Objective
To evaluate the clinical effects and safety of polymyxin B on ventilator-associated pneumonia caused by pandrug-resistant Acinetobacter baumannii (PDR-AB) in patients with chronic obstructive pulmonary disease (COPD).
Methods
COPD patients who were diagnosed as ventilator-associated pneumonia caused by PDR-AB and treated with polymyxin B between January 2015 and August 2016 in this hospital were included in this retrospective study. The patients’ symptoms, vital signs, and the results of laboratory examinations were recorded before and after treatment. The clinical cure rates, microbiological eradication rates, mortality and safety were also measured.
Results
A total of 11 cases were included in this study. Mean time of therapy was 10 days, ranged 8-13 days. After treatment with polymyxin B, most of the patients’ clinical symptoms, signs, and results of laboratory tests as well as imaging examinations were significantly improved. Seven cases had clinical response, and the clinical efficacy rate was 63.6%; 8 cases achieved bacteriological eradication, with the bacteriological eradication rate of 72.7%. Four patients died, and the overall mortality was 36.4%. Only 1 case discontinued treatment with polymyxin B because of the drug fever.
Conclusions
Polymyxin B might be an alternative option for COPD patients with ventilator-associated pneumonia caused by PDR-AB, who is non-responder to prior antimicrobial therapy. However, this method should be evaluated cautiously in prospective well-controlled studies.
ObjectiveTo systematically analyze the trend of incidence, mortality and disease burden of chronic obstructive pulmonary disease (COPD) in China from 1994 to 2023, reveal the influence of age-period-cohort factors on COPD in China and the attribution characteristics of risk factors, and provide empirical basis for formulating precise prevention and control strategies. MethodsThe Global Burden of Disease (GBD) 2023 database was used to extract the data of the whole population, gender and age groups of COPD in China from 1994 to 2023. The Joinpoint regression model was used to calculate the annual percentage change (APC) and average annual percentage change (AAPC) of the standardized rate. The age-period-cohort model was adopted to quantify its impacts on the incidence and mortality of COPD. It also analyzed the attributable effects as well as temporal trend characteristics of seven GBD level-3 risk factors (including smoking, ambient particulate matter pollution, occupational exposure, etc.) in Chinese population in 1994 and 2023 on the standardized mortality rate and standardized disability-adjusted life years (DALYs) rate of COPD. ResultsFrom 1994 to 2023, the incidence and mortality of COPD in China showed an upward trend, but the standardized incidence [AAPC=?1.16%, 95%CI (?1.18, ?1.14), P<0.001] and standardized mortality [AAPC=?2.87%, 95%CI (?3.02, ?2.73), P<0.001] decreased significantly, and the decline rate of standardized incidence in females (AAPC=?1.29%) was slightly higher than that in males (AAPC=?1.04%). The decline rate of standardized mortality in males (AAPC=?3.65%) was higher than that in females (AAPC=?1.94%). The age-period-cohort model revealed a nonlinear increase in the age effect, a graded decline in the cohort effect, and a significant period effect on mortality and male morbidity (P<0.001). In terms of attribution of risk factors, the top three attribution risks of the whole population in 2023 were still smoking, particulate matter pollution and second-hand smoke. Compared with 1994, the attribution of environmental ozone pollution, second-hand smoke, high temperature, smoking and occupational particulate matter/gas/smoke exposure increased, and the attribution of particulate matter pollution decreased. Conclusion From 1994 to 2023, the overall disease burden of COPD in China shows a downward trend. Age and cohort are the core driving factors of the disease, and period factors have a more significant impact on death. The changes in the attribution structure suggest that while consolidating the effectiveness of particulate matter pollution control, it is necessary to strengthen the comprehensive prevention and control strategies of tobacco control, coordinated emission reduction of ozone and multiple pollutants, extreme temperature protection and protection of key occupational groups, so as to continuously reduce the disease burden of COPD.
